Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Infectious Diseases

• Publication date

  2009-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/597384PMID 19284286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α‐2b

  2008cited by this paper
• Modelling hepatitis C virus kinetics during treatment with pegylated interferon α‐2b: errors in the estimation of viral kinetic parameters

  2008cited by this paper
• Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.

  2008cited by this paper
• Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral Therapy

  2007cited by this paper
• Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

  2007cited by this paper
• Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

  2007cited by this paper
• Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop

  2007cited by this paper
• Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 Domain

  2006cited by this paper
• The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002

  2006cited by this paper
• American Gastroenterological Association technical review on the management of hepatitis C.

  2006cited by this paper
• Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

  2006cited by this paper
• Peginterferon and ribavirin for chronic hepatitis C.

  2006cited by this paper
• American Gastroenterological Association medical position statement on the management of hepatitis C.

  2006cited by this paper
• Mechanism of action of interferon and ribavirin in treatment of hepatitis C

  2005cited by this paper
• Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

  2005cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

  2004cited by this paper
• Diagnosis, management, and treatment of hepatitis C

  2004cited by this paper
• Viral dynamics and response differences in HCV‐infected African American and white patients treated with IFN and ribavirin

  2003cited by this paper
• Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

  2003cited by this paper
• First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

  2002cited by this paper
• Gastric adenocarcinoma and kidney transplantation

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover

  1998cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐making

  1988cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury

  1960cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Mathematical Modelling of Spread and Control of the Hepatitis C Virus

  2023cites this paper
• Hepatitis C virus genotype and its correlation with viral load in patients from Kathmandu, Nepal.

  2020cites this paper
• Rapid virologic response in chronic hepatitis C genotype 1: Evaluation of pretreatment factors in patients.

  2020cites this paper
• Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection

  2019cites this paper
• MDR1 gene C3435T polymorphism in chronic hepatitis C patients.

  2018cites this paper
• INTERFERON INDUCIBLE PROTEIN-10 LEVEL AND IL28B GENE POLYMORPHISM AS PREDICTORS OF THE RESPONSE TO PEGYLATED INTERFERON / RIBAVIRIN THERAPY IN EGYPTIAN HCV PATIENTS

  2017cites this paper
• ASSOCIATION OF OBESITY WITH RAPID VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C

  2017cites this paper
• Title : No one size fits all-shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection

  2017cites this paper
• No one size fits all—Shortening duration of therapy with direct‐acting antivirals for hepatitis C genotype 1 infection

  2017cites this paper
• High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV‐infected patients regardless of DPP4 activity

  2016cites this paper
• HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

  2016cites this paper
• Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy

  2016cites this paper
• Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.

  2015influential citation
• Valoración del antígeno del core como alternativa en el cribado rutinario y de urgencia del virus de la hepatitis C

  2015influential citation
• Therapeutic Response to Pegylated Interferon α2 a and Ribavirin in Genotype 4 Chronic Hepatitis C in Sub Saharan Africans

  2015cites this paper
• РОЛЬ ПОЛИМОРФИЗМА ГЕНОВ ЦИТОКИНОВ ПРИ ВИРУСНОМ ГЕПАТИТЕ С

  2014cites this paper
• Association between baseline parameters and end of treatment response to combination of conventional interferon & ribavirin in patients with chronic Hepatitis C

  2014cites this paper
• Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

  2014cites this paper
• Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1

  2014cites this paper
• Therapeutic Response of Black Africans in the Treatment of Genotype 2 Chronic Viral Hepatitis c by Pegylated Interferon-ribavirin

  2014cites this paper
• Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS‐650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C

  2013cites this paper
• Sustained and rapid virological responses in hepatitis C clinical trials

  2013cites this paper
• Predictors of treatment response in patients with hepatitis C 1b genotype

  2013cites this paper
• Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus

  2013cites this paper
• Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons &agr;-2a and &agr;-2b, plus ribavirin

  2013cites this paper
• Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.

  2012cites this paper
• Prevalence of Hepatitis C Virus Genotypes in Mashhad, Northeast Iran

  2012cites this paper
• Development of new IL28B genotyping method using Invader Plus assay

  2012cites this paper
• Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1

  2012cites this paper
• Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.

  2012influential citation
• Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.

  2012cites this paper
• Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.

  2012cites this paper
• Tizoxanide (2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide) Inhibits Hepatitis C Virus Replication Through Modulation of NS5A Hyperphosphorylation

  2012cites this paper
• SVM MODEL FOR CLASSIFICATION OF GENOTYPES OF HCV USING RELATIVE SYNONYMOUS CODON USAGE

  2012cites this paper
• Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.

  2012cites this paper
• Correlates of high hepatitis C virus RNA load in a cohort of HIV‐negative and HIV‐positive individuals with haemophilia

  2011cites this paper
• 1 IL 28 B genotyping , SNPs rs 12979860 and rs 8099917 , by MELT-1 MAMA PCR analysis ; a useful tool for prediction of therapy response 2 in hepatitis C patients 3 4

  2011cites this paper
• Interleukin-28 B Genotyping by Melt-Mismatch Amplification Mutation Assay PCR Analysis Using Single Nucleotide Polymorphisms rs 12979860 and rs 8099917 , a Useful Tool for Prediction of Therapy Response in Hepatitis C Patients

  2011cites this paper
• Interleukin-28B Genotyping by Melt-Mismatch Amplification Mutation Assay PCR Analysis Using Single Nucleotide Polymorphisms rs12979860 and rs8099917, a Useful Tool for Prediction of Therapy Response in Hepatitis C Patients

  2011cites this paper
• Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

  2011cites this paper
• 'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?

  2011cites this paper
• High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients

  2010cites this paper
• apid prediction of sustained virological response in patients chronically infected ith HCV by evaluation of RNA decay 48 h after the start of treatment with egylated interferon and ribavirin

  2010cites this paper
• Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.

  2010cites this paper
• Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle.

  2010cites this paper
• Application of interferon response-related gene array to the antiviral treatment outcome in chronic hepatitis C.

  2010cites this paper
• A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients

  2010cites this paper
• Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C

  2010cites this paper
• Baseline Prediction of Combination Therapy Outcome in Hepatitis C Virus 1b Infected Patients by Discriminant Analysis Using Viral and Host Factors

  2010cites this paper
• Treatment with peginterferon versus interferon in Chinese patients with hepatitis B.

  2010cites this paper
• Host genetic basis for hepatitis C virus clearance: a role for blood collection centers

  2010cites this paper
• Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: a hardwiring issue?

  2009cites this paper
• HCV genotyping using statistical classification approach

  2009cites this paper
• Is onerous regulation responsible for adenovirus outbreaks?

  2009cites this paper
• Reply to Antonucci et al

  2009cites this paper
• Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels.

  2009cites this paper
• Racial Differences in HCV Kinetics During Interferon-Based Therapy

  2009cites this paper